LUCID CAPITAL MARKETS Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $59
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $59.
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $59.